Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jawahar Mehta to Cardiovascular Diseases

This is a "connection" page, showing publications Jawahar Mehta has written about Cardiovascular Diseases.

 
Connection Strength
  
 
 
10.840
  
  1. Kumar A, Chidambaram V, Mehta JL. Vegetarianism, microbiota, and cardiovascular health: looking back, and forward. Eur J Prev Cardiol. 2022 10 20; 29(14):1895-1910.
    View in: PubMed
    Score: 0.589
  2. Mathur P, Kadavath S, Marsh JD, Mehta JL. Chronotherapy for hypertension: improvement in patient outcomes with bedtime administration of antihypertensive drugs. Eur Heart J. 2020 12 21; 41(48):4577-4579.
    View in: PubMed
    Score: 0.518
  3. Shoar S, Hosseini F, Naderan M, Mehta JL. Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19. Am J Cardiol. 2020 11 15; 135:50-61.
    View in: PubMed
    Score: 0.508
  4. Barill? F, Bassareo PP, Calcaterra G, Romeo F, Mehta JL. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. J Cardiovasc Med (Hagerstown). 2020 09; 21(9):630-633.
    View in: PubMed
    Score: 0.508
  5. Romeo F, Calcaterra G, Barilla F, Mehta JL. Coronavirus disease 2019 infection and the cardiovascular system. J Cardiovasc Med (Hagerstown). 2020 06; 21(6):403-405.
    View in: PubMed
    Score: 0.499
  6. Mehta JL. Suicide, Depression, and Cardiovascular Disease. JACC Heart Fail. 2020 06; 8(6):519.
    View in: PubMed
    Score: 0.499
  7. Mehta JL. Response to 'Late repercussions of assisted reproductive technology'. Eur Heart J. 2019 11 21; 40(44):3656.
    View in: PubMed
    Score: 0.481
  8. Mehta JL, Bavineni M. Premature birth, infections, and atherosclerotic cardiovascular disease. Eur Heart J. 2019 10 14; 40(39):3275.
    View in: PubMed
    Score: 0.477
  9. Saad M, Abdelaziz HK, Mehta JL. Aspirin for primary prevention in the elderly. Aging (Albany NY). 2019 09 06; 11(17):6618-6619.
    View in: PubMed
    Score: 0.474
  10. Saad M, Salehi N, Ding Z, Mehta JL. Blood pressure target in diabetics: how low is too low? Eur Heart J. 2019 07 01; 40(25):2044-2046.
    View in: PubMed
    Score: 0.468
  11. Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, Kon DLC, Roberts DH, Bhatt DL, Aronow HD, Abbott JD, Mehta JL. Aspirin for Primary Prevention of Cardiovascular?Events. J Am Coll Cardiol. 2019 06 18; 73(23):2915-2929.
    View in: PubMed
    Score: 0.467
  12. Bavineni M, Wassenaar TM, Agnihotri K, Ussery DW, L?scher TF, Mehta JL. Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood. Eur Heart J. 2019 04 07; 40(14):1107-1112.
    View in: PubMed
    Score: 0.461
  13. Mathur P, Thanendrarajan S, Paydak H, Vallurupalli S, Jambhekar K, Bhatti S, Schinke CD, Davies FE, Mehta JL. Cardiovascular complications of multiple myeloma in the elderly. Expert Rev Cardiovasc Ther. 2017 Dec; 15(12):933-943.
    View in: PubMed
    Score: 0.419
  14. Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RDR, Romeo F, Mehta JL. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol. 2017 Oct 01; 120(7):1122-1128.
    View in: PubMed
    Score: 0.408
  15. Ayyadevara S, Mercanti F, Wang X, Mackintosh SG, Tackett AJ, Prayaga SV, Romeo F, Shmookler Reis RJ, Mehta JL. Age- and Hypertension-Associated Protein Aggregates in Mouse Heart Have Similar Proteomic Profiles. Hypertension. 2016 May; 67(5):1006-13.
    View in: PubMed
    Score: 0.372
  16. Pothineni NV, Mehta JL. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 09 03; 373(10):977-8.
    View in: PubMed
    Score: 0.359
  17. Mainali P, Pant S, Rodriguez AP, Deshmukh A, Mehta JL. Tobacco and cardiovascular health. Cardiovasc Toxicol. 2015 Apr; 15(2):107-16.
    View in: PubMed
    Score: 0.349
  18. Dai Y, Dai D, Mercanti F, Ding Z, Wang X, Mehta JL. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetol. 2013 Dec; 50(6):827-35.
    View in: PubMed
    Score: 0.309
  19. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, Sawamura T. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther. 2011 Oct; 25(5):495-500.
    View in: PubMed
    Score: 0.274
  20. Deshmukh A, Mehta JL. Statins and renal disease: friend or foe? Curr Atheroscler Rep. 2011 Feb; 13(1):57-63.
    View in: PubMed
    Score: 0.261
  21. Mehta JL, Szwedo J. Circulating endothelial progenitor cells, microparticles and vascular disease. J Hypertens. 2010 Aug; 28(8):1611-3.
    View in: PubMed
    Score: 0.252
  22. Bansal D, Mehta JL. Current approaches to cardiovascular disease risk assessment. Indian Heart J. 2008 Mar-Apr; 60(2 Suppl B):B19-22.
    View in: PubMed
    Score: 0.213
  23. Marwali MR, Mehta JL. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost. 2006 Oct; 96(4):401-6.
    View in: PubMed
    Score: 0.193
  24. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006 Oct 01; 98(7):923-8.
    View in: PubMed
    Score: 0.191
  25. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol. 2005 Sep; 20(5):407-16.
    View in: PubMed
    Score: 0.179
  26. Schr?r K, Mehta P, Mehta JL. Cardiovascular risk of selective cyclooxygenase-2 inhibitors. J Cardiovasc Pharmacol Ther. 2005 Jun; 10(2):95-101.
    View in: PubMed
    Score: 0.176
  27. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol. 2004 Sep; 19(5):488-93.
    View in: PubMed
    Score: 0.167
  28. Calcaterra G, Bassareo PP, Spaccarotella CA, Barill? F, Sciomer S, Vadal? G, de Gregorio C, Romeo F, Mehta JL, Mattioli AV. The long-term cardiovascular impairment of COVID 19: need for clarity in definition and terminology. Minerva Cardiol Angiol. 2024 Feb; 72(1):24-31.
    View in: PubMed
    Score: 0.157
  29. Cheng W, Cui C, Liu G, Ye C, Shao F, Bagchi AK, Mehta JL, Wang X. NF-?B, A Potential Therapeutic Target in Cardiovascular Diseases. Cardiovasc Drugs Ther. 2023 06; 37(3):571-584.
    View in: PubMed
    Score: 0.144
  30. Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521.
    View in: PubMed
    Score: 0.119
  31. Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018 01 08; 113(1):5.
    View in: PubMed
    Score: 0.105
  32. Jensen HA, Mehta JL. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Rev Cardiovasc Ther. 2016 Sep; 14(9):1021-33.
    View in: PubMed
    Score: 0.095
  33. Yan M, Mehta JL, Zhang W, Hu C. LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther. 2011 Oct; 25(5):451-9.
    View in: PubMed
    Score: 0.068
  34. Mango R, Vecchione L, Raso B, Borgiani P, Brunetti E, Mehta JL, Lauro R, Romeo F, Novelli G. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opin Pharmacother. 2005 Dec; 6(15):2565-76.
    View in: PubMed
    Score: 0.046
  35. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021 02; 232:10-22.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.